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M. pprlrer: Dr. Colucci, you made anumber of excellent 
points in your presentation. One point that should be em- 
phasized is the importance ofdose. The dose of mihiuone 
that was evaluated in the PROMISE trial was arbitrarily 
chosen to pmduce a sign&ant positive inotropic effect. 
That might not have been the correct decision. I do not think 
thattheresultsdthePROMISEtrialarerelatedto~~ 
selection because the proarrhythmic a tions and serious 
cardiovascular side effects of milrinoue were observed in 
patients in both functional class III and class IV. 
A. Caatsr I want o make a point about he importance of
dosiug frequency for positive &tropic agents. The original 
animal experiments with dobutamine used infusions of short 
duration. When these studies were translated tothe care of 
patients, a 48-h infusion was used. Perhaps better esults 
would have been found if the duration of the infusion had 
been shorter. We recently completed a trial of dobutamine 
using half-hour infusions/day for 3 weeks. This dosing regi- 
men improved exercise tolerance and caused up-regulation 
of beta-receptors. Hence, it may be inappropriate to admiu- 
isteraninotmpicdrugsoastoproduceapharmacologic 
elfect for 24 h/day. 
w.coluccbTheleausfewpublisheddataonthesafetyof 
intermittent dobutamine therapy. Many of the deaths in the 
dobutaminestudyweresuddendeathsthatocuuredduring 
the infusion of the drug at home. Oue wonders whether 
dobtuuunine would have increased mortality if infusion ofthe 
atug had been more closely monitored. 
P.I%taIe=WiIsamIamnotconvincedthattheresultsof 
controlled cbnical trials with digitalis upport arole for the 
drup in the treatment of heart failure. Most of the studies 
demonstrating its utility are withdrawal studies. Such stud- 
ies, even ifapparently positive, are di&ult to interpret and 
arecompatiblewithadfz&&mse%ctofthedrug.For 
example, if a drug iqiures the heart but still produces a
hernodynamic effect, withdrawal of the drug will result in 
chnical deteriorution, but such deterioration might not have 
ocauredifthepatienthadnotbeenoxposedtolong-tenn 
therapywiththedrug. Withdrawalstudiesdonotaddressthe 
tilndamental question conce&gdigitalis:Inapatientre- 
ceivingappropiatedosesofadhueticdrugandauangiotensin- 
914vubYthcAmuicMcosescdcardioloav 
converting enzyme inhibitor, does the addition of digoxin 
produce further benefit? My answer to this question at the 
present time is uo. The data from the RADIANCE study 
(Packer et al. Withdrawal of digoxin from patients with 
chronic heart failure tteated with angiotensin-convertiug 
enzyme inhibitors. N Engl J Med 1993;329: l-7) simply is not 
relevant to this question. 
T. Smltlu I lind it hard to agree with your interpretation of 
the results of the RADIANCE Study. In that study, a group 
of patients with heart failure were maintained on dimetic 
drugs aad angiotensinconverting e zyme inhibitors in opt& 
mal doses. For these patients, it made a gmat deal of 
difference whether or not they were also receiving digoxio. 
P.PoaleWllsmuOneofthekeypointsofthestudywas 
that the withdrawal of diixin led to an increased require- 
ment for diuretic drugs and an angiotensiu~onverting en- 
zyme inhibitor. This is a problem. The study should have 
been designed to permit increases in the dose of the latter 
two agents thmughout the study whenever the clinical need 
arose. Then we could assess whether patients ttcated witb 
digoxiufared~ybetterthallp&llt!8notlw%ivbQtlledrttg. 
M.Padu!rrActually,thatsuggestionwasfollowediutlle 
RADIANCE trial. Before enrollment iu the study, the pa- 
tients’ medical regimen was optimixed using three drugs: 
digoxiu,diureticdntgsaudaconvertingenzymeiuhib& 
and while using these drugs, most patients had only mild 
symptoms of heart faihlre (class II). Then, patients were 
mndomly assigned to continue digoxin or to have placebo 
substituted for digoxin. Patieuts rundomized toplacebo had 
a 6fold increase inthe risk ofworseninp heart failure dmin~8 
the 12-week folIow-up eriod, and this risk was nut siplpl~ 
mauifested as au increase iu the need for diuretic drugs. In 
this study the withdrawal of digoxin led to serious Clinical 
problems-includinghospitt&&mforworseniagheartfaiE 
ur+despite appropriate inaeasesinthedosesofdimetic 
m. 
B.PfttrIamoonoeraedabouttheuseddigitalis.In 
animal models iu which recurrent episodes of myocardial 
~hemia~produccd,WeklloWthatdigitalisSensiti=the 
myocardium tothe development of catecholamhm-induced 
arrhythmia. 
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Dr. ct&lcci, I am wncemed about your sugqestion that 
we administer positive inouopic agents primarily topatients 
withmildheartfailure.Suchpatientsareatgreaterriskof 
sudden death than are patients with svm hut fidue and 
&ouM probably not receive drugs that can exace&a@ 
ven&uhuarrhythmias. IMhermore, mild heart fbilme can 
progreMrapidlyto!3everehealt%hlreatanytime,sotbat 
WCcannotCOUEM!theUSedpo!3itiV~~~tSto 
patients with mild disease. 
w.cdul!drIdidnotpKqlosethatwedothat.Imerely 
wanted to point out that we have not really explored the 
possibility. The fact that patients pIogre!%% h fimctional 
class III to class IV makes it ahnost impossiie to qive a drug 
toapatientinclassIIIthatisknowntobedangeroustoa 
patient inclass IV. Yet if safer agents were developed in the 
fittum, one would be iuterested in knowing whether they 
were useiitl in mild heart feilure. 
MTlulwr:Inaddiiontoitspositivehm&opiceifects, 
digitalisruducestheactivation ofneurohormonal systems by
enhancing the responsiveness of cardiac barore&xes, in a 
manuersimilartothatoftheveratrumaMoids.IIence,we 
&notreaUyu&mtandwhichm&mismofaction(ii- 
tropic or nemogenic) contributes to the cl&al eifect of the 
druq. Dr. Smith, you have worked with many diiferent 
di@aliscompou&.Isitpossibletodesiguadigitalistypeof 
drugthatexertseEectsp&uuilyonneurog& mecha&ms 
ratherthanoncar3iaccontractihty7Gneoftheunique 
features of digit& is that it causes sympathetic withdrawal 
atthesametimethatithasaninotropice&ctonthe 
myocardium. This inobopic eifect supports the myocardium 
as sympathetic stimulation is withdruwn. Is the balance 
betweentheSetwoeEectsthesameamongthehuqenumber 
of derivatives of digit&? 
T. SmIthr Many years ago we produced a variety of 
digitalis derivatives byadding a positive or negative charge 
to the molecule. The charqed drug did not penetrate into the 
cerebrospinal tlui&uulike digitalis tself. Yet, the char@ 
derivatives were just as toxic as the parent drug. These 
studies were Mcult to interpret, howevar, because digitalis 
exerts its neuroexcitatory e&c& by acting on the area 
pcstrema, but this region is one of the few areas of the 
central nervous system that does not have a blood-brain 
barrier ~JUdge GH, Lloyd BL, Greenblatt DI, Smith TW. 
Inotr+z and toxic e&&s of a polar cardiac glycoside 
derivative in the dog. Cii Res 1978;43:847-54). 
A Katz We have an excellent way of reducing sympa- 
thetic stint&ion of the heart without the side effects of 
positive inotropism: beta-blockem. 
M. Thamsw Beta-blockers only block the eifects of the 
sympathetic nervous system on the myocardium. They do 
not a&t the vasoconst&tor effects of the system on the 
peripheral circulation, although t ey may decrease the re- 
lease of renin by the kidney. The reason for emphasii the 
neurogenic effect of digit&3 is to underscore the impormnce 
oftheperiphery.Idoaotthinkwecanfocuswlyoathe 
heart when we talk about heart failure. 
A. ICatw I think that he heart is the problem inheart 
failure and the periphery just responds to the primary 
abnormahty in the heart. 
S.Ywmf. In the Digitalis Trial sponsored bythe National 
Heart, Lung, and Blood Institute, 50% of the patients have 
never previously received digitalis whereas 50% have had 
long-term treatment with the drug. Given this distribu’rion, 
we will be able to determine whether the muIts of trials of 
diixin withdrawal can bc extrapolated o trials in which 
digoxin sintroduced. 
